Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT01050946 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related…(Haplo/Cord) | Phase 2 | terminated | Jan 18, 2010 | Medical College of Wisconsin | Only one patient was enrolled. Due to low accrual study was terminated | Enrollment / accrual |
| NCT02000986 | Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger… | N/A | withdrawn | Dec 4, 2013 | Virginia Commonwealth University | Slow accrual | Enrollment / accrual |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | Phase 1 | withdrawn | Dec 20, 2007 | University of Arkansas | no accrual | Enrollment / accrual |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell… | Phase 2 | withdrawn | Dec 20, 2010 | UNC Lineberger Comprehensive Cancer Center | No patients enrolled and funding has been withdrawn. | Enrollment / accrual |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's… | Phase 3 | terminated | Aug 15, 2006 | Biogen | Enrollment challenges due to changes in standards of care resulted in premature termination. No… | Safety / toxicity |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2010 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT01119794 | Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That… | Phase 2 | terminated | May 10, 2010 | Brown University | lack of accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | Phase 1 / Phase 2 | terminated | Aug 6, 2009 | German Low Grade Lymphoma Study Group | Predefined termination criterion of \> 10 patients without CR or PR was matched. | Other (stated, no rule matched) |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | Phase 2 | terminated | Nov 8, 2005 | New Mexico Cancer Research Alliance | Low rate of accrual | Enrollment / accrual |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute…(ALLPhi) | Phase 1 / Phase 2 | terminated | May 20, 2009 | Rony Schaffel | The study was terminated due to excessive toxicity and low compliance to the protocol scheme. | Safety / toxicity |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Phase 2 | terminated | Aug 1, 2006 | Mirati Therapeutics Inc. | not stated | Not stated |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed… | Phase 2 | terminated | Oct 15, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | withdrawn | May 1, 2013 | Stefan Schieke MD | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | Phase 1 / Phase 2 | terminated | Aug 11, 2005 | University of Michigan | Slow enrollment | Enrollment / accrual |
| NCT02150928 | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze®… | Phase 2 | withdrawn | May 30, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Enrollment terminated in 2005 to focus on Phase 3 study enrollment. | Enrollment / accrual |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple… | Phase 2 | withdrawn | Mar 10, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 27, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab… | Phase 3 | withdrawn | Apr 27, 2006 | GlaxoSmithKline | This study has been cancelled prior to enrollment | Enrollment / accrual |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | Phase 2 | withdrawn | Jul 19, 2007 | Meir Medical Center | We found out that there is another study on the same issue | Other (stated, no rule matched) |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients… | Phase 4 | withdrawn | Oct 20, 2005 | Novartis | not stated | Not stated |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed… | Phase 2 | withdrawn | Jun 30, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | not stated | Not stated |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Feb 4, 2010 | University of Arkansas | Slow accrual; PI left primary institution | Investigator |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | Phase 2 | terminated | Sep 21, 2005 | International Extranodal Lymphoma Study Group (IELSG) | After IELSG25A study amendment, patients subject of the present study were eligible for inclusion… | Other (stated, no rule matched) |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | N/A | terminated | Apr 9, 2010 | University of Minnesota | Due to slow accrual | Enrollment / accrual |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular,… | Phase 1 / Phase 2 | terminated | Feb 18, 2004 | Genzyme, a Sanofi Company | not stated | Not stated |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | the data collected are enough to obtain a qualitative analysis. | Other (stated, no rule matched) |
| NCT00185679 | Haploid Allogeneic Transplant Using the CliniMACS System | Phase 2 | terminated | Sep 16, 2005 | Ginna Laport | This study was superseded by the subsequent study IRB-15919 (NCT01050764) | Other (stated, no rule matched) |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients… | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory… | Phase 3 | terminated | Mar 16, 2004 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous… | Phase 2 | withdrawn | Jan 25, 2010 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 26, 2015source: clinicaltrials